Pharma Symposium Canada is the place to meet government, industry representatives and thoughtleaders to gain the insight you need to navigate the changing world of market access.

Public and private payers, as well as the manufacturing sector, still face a very challenging and complex environment in which to bring new therapies to market, and must find a way to manage their cost so they can be accessed by Canadian patients. The newer, innovative biologic medications, and the greater number of generic biosimilars on the horizon, will bring both greater efficacy and higher price tags to an already financially strained healthcare system.

While the immediate reaction may be to resist these new therapies because of their price, have we really looked at their impact overall? Some people believe we can’t afford a national pharmacare program that would include both these new therapies and those for patients with rare diseases and their high prices. But have we looked at the whole picture? Perhaps the real question is – can we afford not to?

A further question is – can we afford not to re-examine the current path to market here in Canada and root out those inefficiencies that only add to the eventual cost of new products without adding any value? Both of these issues would significantly impact not only market access strategies, but also Canada’s competitiveness as a place to invest, and the Canadian healthcare system as a whole.

The Canadian Institute’s Pharma Symposium Canada will provide an open forum for informed discussion to improve access by patients to needed medication, the sustainability of the healthcare system, and an improved market access environment for industry.

Explore the critical issues faced today by both the public and private sectors in providing Canadians with the medications they need. Take advantage of this opportunity to network with your peers, discover new ways to collaborate, and join in the interactive discussions that will provide the foundation for your future strategies.

Engage with leading experts, including:

  • Dr. Luc Boileau, President and Chief Executive Officer, Institut national d’excellence en santé et services sociaux (INESSS)

  • Douglas Clark, Executive Director, Patented Medicine Prices Review Board (PMPRB)

  • Brent Fraser, Vice-President of Pharmaceutical Reviews, Canadian Agency for Drugs and Technologies in Health (CADTH)

Register for this information-packed event today! Secure your seat by calling 1-877-927-7936, emailing us or registering online .